Quote:

---

Recknor is a clinical physician. I don't think Recknor has any experience with receptor occupancy technical details. How did he manage to fix what Rahman could not?

---

We have a CRO that is not Amarex and Dr. Recknor has participated in over 100 trials. He's like the East Coast version of Dr. Lalezari.

Quote:

---

Seems to me that Recknor has no prior experience in anything leronlimab related, yet he is able to solve many substantial problems.

---

Flow cytometry is flow cytometry no matter what the molecule is. If I could eventually figure out some things about leronlimab I'm sure it took him no time to get up to speed.

Dr. Nitya Ray was the only one who knew how to make leronlimab when he came onboard because he figured out and ran the larger production processes for Progenics.

Quote:

---

Last year, Cytodyn's annual meeting was held on September 30.

I doubt anything will read out before that.

---

I think the latest that could be pushed out is mid October. Should know about BTD for cancer by then with possibly early data. Longhaulers topline results. If they can get the Brazil trial protocols approved ASAP and very fast recruitment then just maybe they can can get very early interim results out.